Webcast

Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team

Launch Date
12/16/2025
Credit Amount
0.5
Credit Expires
12/16/2026
This activity is part of a series

Faculty

Jane L. Meisel, MD, FASCO
Moderator
Professor of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology
Associate Vice-Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, GA
Xiaoxian (Bill) Li, MD, PhD
Professor of Pathology
Department of Pathology and Laboratory Medicine
Emory School of Medicine
Atlanta, GA
Hatem Soliman, MD
Senior Member, Departments of Breast and Immunology
Medical Director, Clinical Trials Office
Moffitt Cancer Center and Research Institute
Professor, Department of Oncologic Sciences
College of Medicine University of South Florida
Tampa, FL
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.

In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of HER2 biology and explain why new testing and interpretation methods for HER2-low and ultralow expression in mBC are emerging. Through expert discussion, they explore key evidence driving this shift and what it means for clinical practice moving forward.

.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the clinical implications of HER2-low and ultra-low expression in patients with mBC to apply appropriate clinical strategies for patients based on tumor molecular subtype
  • Evaluate the clinical efficacy and application of ADCs in HER2-low and ultra-low expressing mBC to inform evidence-based treatment decisions in clinical practice

Financial Support

Supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Target Audience

Medical oncologists and pathologists

Credit Information

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and EfficientCME. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.   

Physician Associates (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 12/16/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPath

This activity meets the requirements and has been registered to offer credit for the American Board of Pathology for lifelong learning (CME).

Canadian Physicians who wish to claim credit must select both ACCME and MOC certificates.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Jane L. Meisel, MD, FASCO, reports the following financial relationships:

Advisory Board: AstraZeneca; Olema Oncology; Pfizer Inc.; and Sermonix Pharmaceuticals

Consultant: AstraZeneca; Genentech, Inc.; GSK; Novartis Pharmaceuticals Corporation; Olema Oncology; Pfizer Inc.; and Sermonix Pharmaceuticals

Research Support: AstraZeneca; Olema Oncology; and Sermonix Pharmaceuticals

Xiaoxian (Bill) Li, MD, PhD, reports the following financial relationships:

Advisory Board: Lilly and Roche

Consultant: Cancer Expert Now, LLC

Research Support: Champions Oncology, Inc.

Hatem Soliman, MD, eports the following financial relationships:

Advisory Board: AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; and Pfizer Inc./Arvinas

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Sarah Hertich (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-113-121625-90

Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
Event Date: 12/16/2025
Begin

Activities in the Series

12/17/2025

Methodologies for HER2-Low and Ultralow IHC: A Guided Laboratory Case Walk-through for Pathologists

0.5
Begin Learn More